This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Immunome, Inc.. Active years: 2024.
Company Filing History:
Years Active: 2024
Title: Philippe Marguet: Innovator in Cancer Therapeutics
Introduction
Philippe Marguet is a notable inventor based in San Carlos, CA (US). He has made significant contributions to the field of cancer therapeutics through his innovative work on EphA2 antibodies. His research focuses on developing antibodies that preferentially target tumor tissues, providing new avenues for cancer treatment.
Latest Patents
Philippe Marguet holds a patent for EphA2 antibodies. This patent describes antibodies that bind preferentially to tumor tissue rather than normal tissue, specifically targeting the EphA2 protein. These antibodies are instrumental in methods aimed at inducing an immune response and inhibiting tumor cell growth. Additionally, the patent outlines methods for producing these antibodies, showcasing his commitment to advancing cancer therapies.
Career Highlights
Philippe Marguet is associated with Immunome, Inc., a company dedicated to developing innovative therapeutic solutions. His work at Immunome has positioned him as a key player in the biotechnology sector, particularly in the development of targeted cancer therapies. His expertise and innovative approach have led to advancements that could significantly impact cancer treatment.
Collaborations
Philippe collaborates with talented professionals in his field, including Iraz T Aydin and Ngan Nguyen Atkins. These collaborations enhance the research and development efforts at Immunome, fostering an environment of innovation and discovery.
Conclusion
Philippe Marguet's contributions to the field of cancer therapeutics through his EphA2 antibodies represent a significant advancement in targeted cancer treatment. His work continues to inspire and pave the way for future innovations in the fight against cancer.